Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced Intensity Conditioning (RIC) for the Treatment of Hematological Diseases [MT2015-32]

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT02661035
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-28T10:39:34.711502+00:00
Published At
2023-09-21T00:00:00+00:00
Record Updated At
2023-09-21
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Acute Myelogenous Leukemia", "Acute Lymphocytic Leukemia", "Chronic Myelogenous Leukemia", "Plasma Cell Leukemia", "Myelodysplastic Syndromes", "Chronic Lymphocytic Leukemia", "Small Lymphocytic Lymphoma", "B-Cell Lymphoma", "Follicular Lymphoma", "Lymphoplasmacytic Lymphoma", "Mantle-Cell Lymphoma", "Prolymphocytic Leukemia", "Lymphoblastic Lymphoma", "Burkitt\u0027s Lymphoma", "Non-Hodgkin\u0027s Lymphoma", "Multiple Myeloma", "Myeloproliferative Syndromes", "Hematological Diseases"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2023-09-21"
protocolSection.identificationModule.nctId
"NCT02661035"
protocolSection.identificationModule.officialTitle
"Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced Intensity Conditioning (RIC) for the Treatment of Hematological Diseases [MT2015-32]"
protocolSection.statusModule.overallStatus
"COMPLETED"
protocolSection.designModule.phases
["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
""

Study condition terms

  • Acute Myelogenous Leukemia (protocolSection.conditionsModule.conditions)
  • Acute Lymphocytic Leukemia (protocolSection.conditionsModule.conditions)
  • Chronic Myelogenous Leukemia (protocolSection.conditionsModule.conditions)
  • Plasma Cell Leukemia (protocolSection.conditionsModule.conditions)
  • Myelodysplastic Syndromes (protocolSection.conditionsModule.conditions)
  • Chronic Lymphocytic Leukemia (protocolSection.conditionsModule.conditions)
  • Small Lymphocytic Lymphoma (protocolSection.conditionsModule.conditions)
  • B-Cell Lymphoma (protocolSection.conditionsModule.conditions)
  • Follicular Lymphoma (protocolSection.conditionsModule.conditions)
  • Lymphoplasmacytic Lymphoma (protocolSection.conditionsModule.conditions)
  • Mantle-Cell Lymphoma (protocolSection.conditionsModule.conditions)
  • Prolymphocytic Leukemia (protocolSection.conditionsModule.conditions)
  • Lymphoblastic Lymphoma (protocolSection.conditionsModule.conditions)
  • Burkitt's Lymphoma (protocolSection.conditionsModule.conditions)
  • Non-Hodgkin's Lymphoma (protocolSection.conditionsModule.conditions)
  • Multiple Myeloma (protocolSection.conditionsModule.conditions)
  • Myeloproliferative Syndromes (protocolSection.conditionsModule.conditions)
  • Hematological Diseases (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.